Taken together, in all three models, the most efficient growth inhibition of xenografts was achieved with a combination C-KRAS/PIK3CA-esiRNA (red, Fig 2B–2D; Table 1), indicating that the combined inhibition of two branches of the EGFR-signaling pathway is very effective in slowing down tumor growth. Here, PIK3CA is linked to neoplasm.